Allogene Therapeutics Inc

NASDAQ:ALLO   3:59:45 PM EDT
29.98
+1.38 (+4.82%)
Products

Allogene Therapeutics Announces Preclinical Findings Supporting Allo-605, First Anti-Bcma Turbocar T Cell Therapy

Published: 12/07/2020 16:21 GMT
Allogene Therapeutics Inc (ALLO) - Allogene Therapeutics Inc - Announced Preclinical Findings Supporting Allo-605, First Anti-bcma Turbocar T Cell Therapy.
Allogene Therapeutics Inc - Allo-605 Demonstrated Enhanced Killing of Multiple Myeloma Cells and Persistence Relative to Bcma Car T.
Allogene Therapeutics Inc - Investigational New Drug Application for Allo-605 Expected in First Half of 2021.